- Home
- OPP vs TKNO Comparison
OPP vs TKNO Comparison
Compare OPP & TKNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OPP | TKNO |
|---|---|---|
| Founded | 2010 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 204.0M | 236.6M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | OPP | TKNO |
|---|---|---|
| Price | $7.83 | $4.60 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 108.0K | ★ 118.8K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 14.41% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $39,801,000.00 |
| Revenue This Year | N/A | $8.79 |
| Revenue Next Year | N/A | $10.52 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 9.50 |
| 52 Week Low | $7.26 | $3.94 |
| 52 Week High | $8.83 | $10.37 |
Technical Indicators
Market Signals| Indicator | OPP | TKNO |
|---|---|---|
| Relative Strength Index (RSI) | 37.04 | 46.97 |
| Support Level | $7.94 | $4.53 |
| Resistance Level | $8.03 | $4.82 |
| Average True Range (ATR) | 0.07 | 0.26 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 25.00 | 39.62 |
Price Performance
Historical ComparisonAbout OPP RiverNorth/DoubleLine Strategic Opportunity Fund Inc.
RiverNorth/DoubleLine Strategic Opportunity Fund Inc is a closed-end management investment company. The company's investment objective is to seek current income and overall total return.
About TKNO Alpha Teknova Inc.
Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its offer three product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It derives key revenue from United States.